bioRxiv Science⌕ Search

Biology subjects

Griffin, M. N.

Publications and source records attributed to Griffin, M. N..

2 recordsLinked to original sources

Neuronal p38α knockout protects against neurological consequences following repetitive mild traumatic brain injury

Mild traumatic brain injuries (mTBI) can substantially impact quality of life, and repetitive mTBIs (rmTBI) can amplify injury effects compared to a single injury. However, effective clinical treatments remain elusive, largely due to an incomplete understanding of the underlying injury mechanisms. Neuroinflammation has emerged as a key contributor to worse functional outcomes after mTBI/rmTBI. While microglia are traditionally viewed as primary mediators of post-injury inflammation, accumulating evidence suggests neurons play an immunomodulatory role in initiating the rmTBI inflammatory cascade through activation of intracellular proinflammatory pathways like p38 MAPK and secretion of cytokines that, in turn, stimulate microglial activation. Here, we tested whether inducible neuronal p38 knockout protects against functional, immune, and cerebrovascular consequences of a weight-drop closed head injury model of rmTBI. A battery of functional assays was conducted 4 weeks post-injury, and tissues were collected at both 4 hours and 4 weeks following final CHI. In males, neuronal p38 knockout protected against injury-induced depressive-like behavior, hyperactivity, synaptic loss, microglial reactivity, cytokine upregulation, and reduction in cerebral blood flow. In females, neuronal p38 knockout protected against risk-taking behavior and partially protected against cytokine upregulation but had limited effect on microglial reactivity and cerebral blood flow. Together, these findings identify neuronal p38 as a sex-dependent driver of rmTBI-associated neurological consequences, and they support neuronal p38-immune signaling as a mechanistically relevant therapeutic target for future studies.

neuroscience↗

Aβ-42 sidechain deamidation at Q15 and N27 modulate protein aggregation and microglial responses via altered cytokine production and CD68 expression

The progressive aggregation of amyloid beta (A{beta}) monomers into oligomers is a critical factor in Alzheimers disease (AD) pathogenesis. Although mutated forms of A{beta} have been shown to display altered aggregation dynamics, the specific effects of deamidated A{beta} on microglial function remain understudied. Our research group previously found that the deamidated variant A{beta}-42-N27D modified A{beta} aggregation, reduced neurotoxicity, and reduced microglial reactivity, but the impact of A{beta}-42 side chain deamidation in general on such parameters remained unclear. Here, we expanded on our prior work by investigating how two site-specific A{beta}-42 mutations (Q15E & N27D), where neutral amide side chains are replaced with negatively charged carboxylic acids, affect aggregation and microglial immune response using a mouse microglial cell line. Size exclusion chromatography revealed that A{beta}-42-Q15E and A{beta}-42-N27D exhibit distinct aggregation profiles compared to A{beta}-42 wild type (WT). Multiplexed analysis of 8 cytokines secreted into the culture medium revealed that A{beta}-42-Q15E and A{beta}-42-N27D decrease the expression of inflammatory cytokines such as IL-6, IP-10, and MIP-1 relative to A{beta}-42-WT. Immunocytochemistry revealed that A{beta}-42-Q15E and A{beta}-42-N27D decrease CD68 expression relative to A{beta}-42-WT. These findings demonstrate that deamidation significantly alters A{beta}-42 aggregation and microglial activation, suggesting structural modifications to A{beta}-42 modulate inflammatory signaling in AD. This work provides a foundation for future studies on A{beta}-42 post-translational modifications as potential therapeutic targets in AD.S

neuroscience↗